Nature Communications (Nov 2021)
Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
- Si-Yang Liu,
- Hua Bao,
- Qun Wang,
- Wei-Min Mao,
- Yedan Chen,
- Xiaoling Tong,
- Song-Tao Xu,
- Lin Wu,
- Yu-Cheng Wei,
- Yong-Yu Liu,
- Chun Chen,
- Ying Cheng,
- Rong Yin,
- Fan Yang,
- Sheng-Xiang Ren,
- Xiao-Fei Li,
- Jian Li,
- Cheng Huang,
- Zhi-Dong Liu,
- Shun Xu,
- Ke-Neng Chen,
- Shi-Dong Xu,
- Lun-Xu Liu,
- Ping Yu,
- Bu-Hai Wang,
- Hai-Tao Ma,
- Hong-Hong Yan,
- Song Dong,
- Xu-Chao Zhang,
- Jian Su,
- Jin-Ji Yang,
- Xue-Ning Yang,
- Qing Zhou,
- Xue Wu,
- Yang Shao,
- Wen-Zhao Zhong,
- Yi-Long Wu
Affiliations
- Si-Yang Liu
- Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
- Hua Bao
- Nanjing Geneseeq Technology Inc.
- Qun Wang
- Fudan University Affiliated Zhongshan Hospital
- Wei-Min Mao
- Zhejiang Cancer Hospital
- Yedan Chen
- Nanjing Geneseeq Technology Inc.
- Xiaoling Tong
- Nanjing Geneseeq Technology Inc.
- Song-Tao Xu
- Fudan University Affiliated Zhongshan Hospital
- Lin Wu
- Hunan Cancer Hospital
- Yu-Cheng Wei
- The Affiliated Hospital of Medical College Qingdao University
- Yong-Yu Liu
- Shenyang Chest Hospital
- Chun Chen
- Fujian Medical University Union Hospital
- Ying Cheng
- Jilin Provincial Tumor Hospital
- Rong Yin
- Jiangsu Cancer Hospital
- Fan Yang
- The People’s Hospital of Peking University
- Sheng-Xiang Ren
- Shanghai Pulmonary Hospital
- Xiao-Fei Li
- Tangdu Hospital
- Jian Li
- Peking University First Hospital
- Cheng Huang
- Fujian Cancer Hospital
- Zhi-Dong Liu
- Beijing Chest Hospital
- Shun Xu
- The First Hospital of China Medical University
- Ke-Neng Chen
- Beijing Cancer Hospital
- Shi-Dong Xu
- Harbin Medical University Cancer Hospital
- Lun-Xu Liu
- West China Hospital of Sichuan University
- Ping Yu
- Sichuan Cancer Hospital
- Bu-Hai Wang
- The Northern Jiangsu People’s Hospital
- Hai-Tao Ma
- The First Affiliated Hospital of Suzhou University
- Hong-Hong Yan
- Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
- Song Dong
- Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
- Xu-Chao Zhang
- Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
- Jian Su
- Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
- Jin-Ji Yang
- Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
- Xue-Ning Yang
- Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
- Qing Zhou
- Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
- Xue Wu
- Nanjing Geneseeq Technology Inc.
- Yang Shao
- Nanjing Geneseeq Technology Inc.
- Wen-Zhao Zhong
- Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
- Yi-Long Wu
- Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
- DOI
- https://doi.org/10.1038/s41467-021-26806-7
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 11
Abstract
Adjuvant gefitinib improves outcomes in non-small cell lung cancer (NSCLC) patients compared to chemotherapy, but not in all cases. Here, the authors find genomic biomarkers of response to gefitinib in NSCLC patients from the ADJUVANT trial, and propose a score to stratify them by potential benefit from the treatment.
